Are you Delivering Guideline-Directed Medical Therapy (GDMT) for your Heart Failure Patients?
Heart Failure syndrome has a 50% five-year mortality even for patients in stage B, presymptomatic phase. Over the last 35 years, many studies have demonstrated classes of medications that can not only reduce the mortality of heart failure, but also improve quality of life and reduce the risk of hospitalization. Major advances have occurred in the last 10 years with sacubitril/valsartan (Entresto) replacing ACEs and ARBs as a more protective agent. In addition, SGL2 Inhibitors (Empagliflozin, Dapagliflozin) have now become standard care for all heart failure patients, even in those without diabetes.